A Phase 3 Multinational, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Ph+ CML Patients in Early Chronic Phase

Trial Profile

A Phase 3 Multinational, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Ph+ CML Patients in Early Chronic Phase

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Radotinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms RERISE
  • Sponsors Il-Yang Pharmaceutical
  • Most Recent Events

    • 22 Sep 2017 Primary endpoint has been met. (Rate of Major Molecular Response(MMR) by 12 months) as per result published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 22 Sep 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 25 Jun 2017 Results assessing the impact of molecular response by 24 months, presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top